Treatment Eligibility of Real-Life Mepolizumab-Treated Severe Asthma Patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Treatment Eligibility of Real-Life Mepolizumab-Treated Severe Asthma Patients

Published:2020-10 Issue:9 Volume:8 Page:2999-3008.e1
ISSN:2213-2198
Container-title:The Journal of Allergy and Clinical Immunology: In Practice
language:en
Short-container-title:The Journal of Allergy and Clinical Immunology: In Practice

Author:

Richards Levi B.,van Bragt Job J.M.H.,Aarab Reim,Longo Cristina,Neerincx Anne H.,Sont Jaap K.,Weersink Els J.M.,Braunstahl Gert-Jan,Brinke Anneke Ten,Bel Elisabeth H.D.,Maitland-van der Zee Anke-Hilse

Funder

Amsterdam UMC

GSK

Novartis

Teva

Chiesi

ALK Abello

AstraZeneca

Sanofi Regeneron

Vectura

Boehringer Ingelheim

Publisher

Elsevier BV

Subject

Immunology and Allergy

Reference33 articles.

1. The prevalence of severe refractory asthma;Hekking;J Allergy Clin Immunol,2015

2. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma;Chung;Eur Respir J,2014

3. Treatable traits: toward precision medicine of chronic airway diseases;Agusti;Eur Respir J,2016

4. Severe and difficult-to-treat asthma in adults;Israel;N Engl J Med,2017

5. Type 2 inflammation in asthma—present in most, absent in many;Fahy;Nat Rev Immunol,2015

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan;Drugs;2024-06

2. Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab;Pediatric Drugs;2023-09-02

3. Real-World Experience on the Use of Mepolizumab from the Severe Asthma Registry of the German Asthma Net (MepoGAN-Study);Journal of Asthma and Allergy;2023-05

4. Characteristics of severe asthma patients on biologics: a real-life European registry study;ERJ Open Research;2023-04-06

5. Patient characteristics and eligibility for biologics in severe asthma: Results from the Greek cohort of the RECOGNISE “real world” study;Respiratory Medicine;2023-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3